Inventiva S.A. (IVA)

$4.6

-0.11 (-2.34%)
Rating:
Recommendation:
-
Symbol IVA
Price $4.6
Beta 1.195
Volume Avg. 0.03M
Market Cap 188.019M
Shares () -
52 Week Range 4.28-15.78
1y Target Est -
DCF Unlevered IVA DCF ->
DCF Levered IVA LDCF ->
ROE -47.69% Strong Sell
ROA -34.96% Strong Sell
Operating Margin -
Debt / Equity 32.41% Neutral
P/E -
P/B 1.71 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IVA news


Mr. Frédéric Cren
Healthcare
Biotechnology
NASDAQ Global Market

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.